基于利润企稳、具吸引力的估值与技术支撑，UNH 是 10 月的买入候选标的，但需等待复苏趋势得到确认。
逐段跳播
不过，让我们进入第三只股票，也就是 UnitedHealth，交易代码 UNH。这只股票完全不同。United Health 经历了一场真正的噩梦。医疗使用率、Medicare Advantage 的压力、政府审查、欺诈担忧、驾驶问题，以及一个接一个的负面头条。
However, let's move on to the third stock, which is UnitedHealth, with the trading symbol UNH. This stock is completely different. United Health have gone through a real nightmare.
Healthcare usage, Medicare Advantage pressures, government scrutiny, fraud concerns, driving issues, and negative headlines one after
但这正是投资变得有意思的地方，因为归根结底，我们必须把新闻头条带来的风险与盈利的力量区分开来。UnitedHealth 上一季度显示出企稳的迹象。营收达到 1120 亿美元，营业利润 80 亿美元，调整后每股收益 6.38 美元。
管理层甚至将全年调整后每股收益预期上调至每股 19.75 美元。这一点很重要。
But this is where the investment becomes interesting, because ultimately we must separate the risks of headlines from the power of profits. UnitedHealth's last quarter showed signs of stabilization.
Revenues reached $112 billion, operating profit $8 billion, and adjusted earnings per share $6.38. Management even raised its full-year adjusted earnings per share forecast to $19.75 per share. This is important.
仍然存在监管风险、偿付风险以及其他行业特有的风险。事实上，与 Medicare Advantage 以及《平价医疗法案》（ACA）参保相关的新政策变化，仍是需要讨论的问题。
There are still regulatory risks, repayment risks , and other sector-specific risks that remain . In fact, the new policy changes relating to Medicare Advantage and enrollment in the Affordable Care Act (ACA) are still issues to be discussed.
而下一个重大考验正迅速临近。United 将于 10 月 13 日公布第三季度财报。因此，我们会密切关注这一点。
And the next major test is fast approaching. United will announce its third-quarter earnings on October 13. Therefore, we will pay close attention to that.
在过去十二个月里，我跟你们说过，这段时间可谓风起云涌。该股仅上涨了 3%，但盘中低点触及 250 区间，高点触及 460 区间。
Over the past twelve months, I've told you it's been a whirlwind. The stock rose by only 3%, but traded at lows in the 250 range and highs in the 460 range.
该股目前的 Edge Score 为 73。该股目前的远期市盈率为 17.5 倍，低于其 5 年平均的 19.7 倍。
The stock currently has an Edge Score of 73. The stock is trading at a forward price-to-earnings ratio of 17.5 times, which is lower than its 5- year average of 19.7 times.
分析师对该股也持乐观态度，给出的 12 个月目标价约为每股 475 美元，这意味着有超过 25% 的潜在上涨空间。市场上最低的目标价就是该股当前所处的交易水平。
Analysts are also optimistic about the stock, setting a 12-month target price of approximately $475 per share, which implies a potential rise of more than 25%. The lowest target price in the market is the level at which the stock is currently trading.
所以，我喜欢这种局面。对于关注技术分析的人来说，我们目前正好位于 200 日移动均线上方，这也可能为该股提供一个支撑区域。
So, I like this situation . For those interested in technical analysis, we are sitting just above the 200-day moving average , which may also provide a support zone for the stock .
所以，从 10 月的角度来看，我感兴趣的是盈利复苏、估值相对历史水平偏低以及前景改善这几方面的组合。但这一转变仍需得到确认，这是我们接下来几周会密切关注的事情。
So, from an October perspective , I'm interested in a mix of recovering earnings, low valuations compared to historical levels , and improved outlook. But the shift still needs to be confirmed, which is something we will be watching closely here in the next few weeks.
UnitedHealth，转型与评估。
UnitedHealth, Transformation and Assessment.
观察点
这个频道对 $UNH 的历次判断
Mark Roussin, CPA 在这只股票上只有这一条判断。